Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).

被引：0
|
作者：
Tan, Antoinette R.
Wong, Serena Tsan-Lai
Warren, Robert D.
Eng-Wong, Jennifer
Liu, Minetta C.
Zelnak, Amelia Bruce
Lin, Yong
Shih, Weichung
Ganesan, Shridar
Grana, Generosa
Isaacs, Claudine
Toppmeyer, Deborah
机构：
[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[2] Lombardi Canc Ctr, Washington, DC USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Mayo Clin, Rochester, MN USA
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] Cooper Univ Hosp, Camden, NJ USA
[7] Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
531
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
    Zembryki, D.
    Gomez, H.
    Koehler, M.
    Koehler, M.
    Johnston, S.
    Pippen, J.
    Florance, A.
    O'Rourke, L.
    Maltzman, J.
    Pivot, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Fulvestrant (F) plus sorafenib (S) as salvage therapy for hormone receptor positive (HR plus ) metastatic breast cancer (MBC) failing prior aromatase inhibitor (AI) treatment.
    Lethert, Kristine H.
    Nauman, Deirdre J.
    Prado, Yolanda
    Seligman, Mark
    Karamlou, Kasra
    Ey, Frederick S.
    Chui, Stephen Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients
    Paul, Devchand
    Vukelja, Svetislava J.
    Holmes, Frankie Ann
    Blum, Joanne L.
    McIntyre, Kristi J.
    Lindquist, Deborah L.
    Osborne, Cynthia R.
    Sanchez, Ines J.
    Goldschmidt, Jerome H.
    Wang, Yunfei
    Asmar, Lina
    Strauss, Lewis
    O'Shaughnessy, Joyce
    NPJ BREAST CANCER, 2019, 5 (1)
  • [34] An indirect comparison of aromatase inhibitors (Als) in the first line treatment of post menopausal women with hormone receptor positive (HR plus ) metastatic breast cancer (MBC)
    Kleijnen, J.
    Riemsma, R.
    Amonkar, M. M.
    Lykopoulos, K.
    Diaz, J. R.
    Forbes, C. A.
    Rea, D. W.
    EJC SUPPLEMENTS, 2010, 8 (03): : 200 - 200
  • [35] Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients
    Devchand Paul
    Svetislava J. Vukelja
    Frankie Ann Holmes
    Joanne L. Blum
    Kristi J. McIntyre
    Deborah L. Lindquist
    Cynthia R. Osborne
    Ines J. Sanchez
    Jerome H. Goldschmidt
    Yunfei Wang
    Lina Asmar
    Lewis Strauss
    Joyce O’Shaughnessy
    npj Breast Cancer, 5
  • [36] Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR plus ) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study.
    Gerratana, Lorenzo
    Ren, Yue
    Reduzzi, Carolina
    Regan, Meredith M.
    Mahtani, Reshma L.
    Ma, Cynthia X.
    DeMichele, Angela
    Meisel, Jane Lowe
    Miller, Kathy
    Jolly, Trevor Augustus
    Riley, Elizabeth Carloss
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya A.
    Ko, Naomi Yu
    Liu, Yuan
    Burstein, Harold J.
    Tolaney, Sara M.
    Cristofanilli, Massimo
    Mayer, Erica L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) plus /- Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)
    Schwartzberg, L. S.
    Hermann, R.
    Blakely, J.
    Richey, S. S.
    Tauer, K. W.
    Childs, B. H.
    CANCER RESEARCH, 2010, 70
  • [38] A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR plus ) locally advanced/metastatic breast cancer (LABC/MBC).
    Lim, Joline Si Jing
    Wong, Andrea Li Ann
    Ow, Samuel Guan Wei
    Eng, Lim Siew
    Sundar, Raghav
    Chan, Gloria H. J.
    Yadav, Kritika
    Heong, Valerie
    Tan, David Shao Peng
    Soo, Ross A.
    Chee, Cheng Ean
    Yong, Wei-Peng
    Goh, Boon C.
    Lee, Soo-Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report
    Sun, Maoben
    Cai, Liangzhen
    Chen, Min
    MEDICINE, 2023, 102 (24) : E33975
  • [40] Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer
    Claudine Isaacs
    Pia Herbolsheimer
    Minetta C. Liu
    Mary Wilkinson
    Yvonne Ottaviano
    Gina G. Chung
    Robert Warren
    Jennifer Eng-Wong
    Philip Cohen
    Karen L. Smith
    Karen Creswell
    Antonella Novielli
    Rebecca Slack
    Breast Cancer Research and Treatment, 2011, 125 : 137 - 143
12345